SEARCH:   Advanced

Blood, 15 February 2006, Vol. 107, No. 4, pp. 1617-1623. Prepublished online as a Blood First Edition Paper on October 27, 2005; DOI 10.1182/blood-2005-08-3254. This Article Full Text (PDF) All Versions of this Article: 2005-08-3254v1 107/4/1617    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Wan, W. Articles by Cheng, M. Search for Related Content PubMed PubMed Citation Articles by Wan, W. Articles by Cheng, M. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 11, 2005 Accepted October 10, 2005 Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large cell lymphoma cells Weihua Wan, Mark S Albom, Lihui Lu, Matthew R Quail, Nadine C Becknell, Linda R Weinberg, Dandu R Reddy, Beverly P Holskin, Thelma S Angeles, Ted L Underiner, Sheryl L Meyer, Robert L Hudkins, Bruce D Dorsey, Mark A Ator, Bruce A Ruggeri, and Mangeng Cheng* Oncology, Cephalon Inc, West Chester, PA, USA Lead Discovery and Profiling, Cephalon Inc, West Chester, PA, USA Chemistry, Cephalon Inc, West Chester, PA, USA * Corresponding author; email: mcheng{at}cepahalon.com. The roles of aberrant expression of constitutively active ALK chimeric proteins in the pathogenesis of ALCL have been well defined, nevertheless, the notion that ALK is a molecular target for the therapeutic modulation of ALK positive ALCL has not been validated thus far. Select fused pyrrolocarbazole (FP) derived small molecules with ALK inhibitory activity were used as pharmacological tools to evaluate whether functional ALK kinase is essential for the proliferation and survival of ALK positive ALCL cells in culture. These compounds inhibited IL-3 independent proliferation of BaF3/NPM-ALK cells in an ALK inhibition-dependent manner and significantly blocked colony formation in agar of mouse embryonic fibroblast (MEF) cells harboring NPM-ALK. Inhibition of NPM-ALK phosphorylation in the ALK positive ALCL-derived cell lines resulted in significant inhibition of cell proliferation and induction of apoptotic cell death, while having marginal effects on the proliferation and survival of K562, an ALK negative leukemia cell line. ALK inhibition resulted in cell cycle G1 arrest and inactivation of ERK1/2, STAT3 and AKT signaling pathways. Potent and selective ALK inhibitors may have therapeutic application for ALK positive ALCL and possibly other solid and hematological tumors in which ALK activation is implicated in their pathogenesis. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Tauzin, H. Ding, K. Khatib, I. Ahmad, D. Burdevet, G. van Echten-Deckert, J. A. Lindquist, B. Schraven, N.-u. Din, B. Borisch, et al. Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts Blood, February 15, 2008; 111(4): 2310 - 2320. [Abstract] [Full Text] [PDF] H. M. Amin and R. Lai Pathobiology of ALK+ anaplastic large-cell lymphoma Blood, October 1, 2007; 110(7): 2259 - 2267. [Abstract] [Full Text] [PDF] C. Voena, C. Conte, C. Ambrogio, E. Boeri Erba, F. Boccalatte, S. Mohammed, O. N. Jensen, G. Palestro, G. Inghirami, and R. Chiarle The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration Cancer Res., May 1, 2007; 67(9): 4278 - 4286. [Abstract] [Full Text] [PDF] K. Ait-Tahar, M. C.N. Barnardo, and K. Pulford CD4 T-Helper Responses to the Anaplastic Lymphoma Kinase (ALK) Protein in Patients with ALK-Positive Anaplastic Large-Cell Lymphoma Cancer Res., March 1, 2007; 67(5): 1898 - 1901. [Abstract] [Full Text] [PDF] M. S. Lim and K. S. J. Elenitoba-Johnson Mass Spectrometry-based Proteomic Studies of Human Anaplastic Large Cell Lymphoma Mol. Cell. Proteomics, October 1, 2006; 5(10): 1787 - 1798. [Abstract] [Full Text] [PDF] D. E. Levy and G. Inghirami STAT3: A multifaceted oncogene PNAS, July 5, 2006; 103(27): 10151 - 10152. [Full Text] [PDF] E. Jacobsen Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type Oncologist, July 1, 2006; 11(7): 831 - 840. [Abstract] [Full Text] [PDF] M. Kasprzycka, M. Marzec, X. Liu, Q. Zhang, and M. A. Wasik From the Cover: Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3 PNAS, June 27, 2006; 103(26): 9964 - 9969. [Abstract] [Full Text] [PDF] R. Piva, R. Chiarle, A. D. Manazza, R. Taulli, W. Simmons, C. Ambrogio, V. D'Escamard, E. Pellegrino, C. Ponzetto, G. Palestro, et al. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas Blood, January 15, 2006; 107(2): 689 - 697. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020